Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
|
|
PharmaCyte Biotech, Inc. (NVLX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ... |
| 02/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/30/2022 |
8-K
| Quarterly results |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/15/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Cooperation Agreement dated August 15, 2022, by and between PharmaCyte Biotech, Inc. and Iroquois Master Fund Ltd. and its affiliates",
"Form of Director Offer Letter",
"PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital; Company Appoints Five New Independent Directors to Reconstituted Board LAS VEGAS, NV, August 15, 2022 -- -- PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte and Iroquois Master Fund Ltd. and its affiliates, the beneficial owners of approximately 6.7% of PharmaCyte’ s outstanding shares of common stock, have signed a Cooperation Agreement that includes naming two of Iroquois’ director designees to PharmaCyte’ s reconstituted Board of Directors. Pursuant to the Agreement, Iroquois’ director designees, Jonathan L. Schechter and Joshua ..." |
|
| 07/28/2022 |
8-K
| Quarterly results |
| 07/21/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
8-K
| Quarterly results |
| 06/15/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 04/13/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/09/2022 |
8-K
| Quarterly results |
| 02/28/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/17/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/09/2021 |
8-K
| Quarterly results |
| 08/23/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results |
| 08/02/2021 |
8-K
| Quarterly results |
| 07/12/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/02/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
| 06/21/2021 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/14/2021 |
8-K
| Quarterly results |
| 06/03/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 10/16/2020 |
8-K
| Quarterly results |
| 04/08/2020 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits |
| 01/21/2020 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/08/2019 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
|
|
|